Saad Z. Usmani, MD, MBA, on Efficacy of Daratumumab, Lenalidomide, and Dexamethasone from the Phase 3 Maia Study

In this podcast, Saad Z. Usmani, MD, MBA, speaks about the efficacy of daratumumab, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma and impaired renal function from the phase 3 Maia Study based on Lenalidomide starting dose. He also presented on this topic at the 63rd ASH Annual Meeting & Exposition.

Additional Resource:

• Usmani SZ, Kumar SK, Plesner T, et al. Efficacy of daratumumab, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma and impaired renal function from the phase 3 Maia study based on lenalidomide starting dose. Paper presented at: 63rd American Society of Hematology Annual Meeting & Exposition; December 11-13, 2021; Virtual. https://ash.confex.com/ash/2021/webprogram/Paper146940.html 

Saad Z. Usmani, MD, MBA, is the chief of myeloma services at Memorial Sloan Kettering Cancer Center in New York, New York.